Clinical Hemp OilsTM

Extraordinary hemp therapeutics reuniting science and Nature.

Our mission is serving your health practice.

Cannacea offers practitioners scientific hemp oil supplements with certified clinical constituency and purity. Through years of research and development, Cannacea was founded to craft the ultimate phytocannabinoid therapeutics. Today, Cannacea excels for your patients’ health.

Partnered with the Realm of Caring Foundationpioneers of CBD awareness, research, and civil rights – to support you and your patients.


Introduction

The Endocannabinoid System (ECS) is involved in multiple physiological and psychological functions of clinical interest. Notably, the ECS and the functions it regulates can be variably modulated by phytocannabinoids. [1-3]

Clinical studies indicate the intake of phytocannabinoids can provide health benefits for some people [4-8, 14, 15, 21, 22]. The efficacy and safety of phytocannabinoid intake appears to improve when delivered in a full spectrum complex instead of in isolation [see subsection].

Clinical applications demand endocannabinoid supplements be science-driven phytocannabinoid preparations with exceptional certified potencies and purity. [4]

CANNACEA – Clinical Phytochemistry and Purity.

  • Formulations based on advanced research, analytics, and development.
  • Rigorously-validated certified organic ingredients, processing, and manufacture in a cGMP Certified facility (BRCGS).

Life Intelligence.TM


Click on the section headings below to discover the science and special qualities of Cannacea hemp oils.

Or directly action one of the following:

CANNABINOID SCIENCE

POTENCIES

PURITY

MACADAMIA NUT OIL


PRACTITIONER SUPPORT

We want to help you provide ultimate phytocannabinoid therapies. We offer healthcare professionals a selection of special opportunities to support your practice, and to optimize the health and safety of your patients:

  • Clinical Use and Safety Resources exclusively for practitioners, developed from leading peer-reviewed science:
    • Clinical Supplement Monograph for Full Spectrum Hemp Oil – includes all data from our Consumer Monograph while adding:
      • Clinical safety data for wide intake range and detailed Adverse Effects cautions.
      • “Low & Slow” up-titration schedules to optimize therapy and safety for each patient’s unique ECS.
      • Clinical perspective on Special Populations (pregnancy & lactation), with recommended intake adjustments (hepatic impairment).
      • Expanded Drug-Supplement Interactions science and recommendations.
      • Clinical high- and low-dose CBD pharmacokinetics with concomitant low-dose THC data.
      • Clinical data for low-risk of Abuse and Dependence.
      • Clinical and Nonclinical Toxicology.
    • 1,000+ Phytocannabinoid-Drug-Supplement Interactions Listing
  • Special Discounts on Cannacea’s leading products for you and your patients.
  • Product Samples and trials for you and your patients.
  • Cannacea products available for sale at your Practice’s products shop.
  • Cannacea “Client Direct” affiliate program for your patients to order Cannacea products directly from our webstore with tracked attribution and commission automatically sent to you.
  • Collaborating on Cannacea product supply for your Clinical Study, Case Study, or White Paper research.
  • Complimentary consultations with the Cannacea Science Team, and with our pioneering cannabis education and research partners – the non-profit Realm of Caring Foundation.
  • Cannacea Newsletter – uncovering recent discoveries in phytocannabinoid science and phytotherapy, the history and archaeology of cannabis and plant use, and more.
  • Further opportunities to collaborate and support your patients and your practice.

If you wish to access our leading cannabinoid therapeutics and expertise – Please schedule a consultation with CANNACEA’s Head of Science, message us, or request product samples:

Information you provide is kept strictly confidential and is never sold. Please view our Privacy Policy for more information.


SUSTAINABILITY

REALM OF CARING FOUNDATION


References
  1. Aizpurua-Olaizola, O et al. (2017). Targeting the endocannabinoid system: future therapeutic strategies. Drug Discovery Today 22(1): 105-110.
  2. Morales, P, Reggio, PH (2017). An Update on Non-CB1, Non-CB2 Cannabinoid Related G-Protein-Coupled Receptors. Cannabis and Cannabinoid Research 2(1): 265-273.
  3. Stasiulewicz, A et al. (2020). A Guide to Targeting the Endocannabinoid System in Drug Design. International Journal of Molecular Sciences 21(8): 2778.
  4. VanDolah, HJ et al. (2019). Clinician’s Guide to Cannabidiol and Hemp Oils. Mayo Clinic Proceedings 94(9): 1840-1851.
  5. Sholler, DJ et al. (2020). Therapeutic Efficacy of Cannabidiol (CBD): A Review of the Evidence from Clinical Trials and Human Laboratory Studies. Current Addiction Reports 7(3): 405-412.
  6. Khan, R et al. (2020). The therapeutic role of Cannabidiol in mental health: a systematic review. Journal of Cannabis Research 2:2.
  7. Abuhasira, R et al. (2018). Epidemiological characteristics, safety and efficacy of medical cannabis in the elderly. European Journal of Internal Medicine 49: 44-50.
  8. National Academies of Sciences, Engineering, and Medicine (2017). The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, DC: The National Academies Press.
  9. Russo, EB, Marcu, J (2017). Cannabis Pharmacology: The Usual Suspects and a Few Promising Leads. Advances in Pharmacology 80: 67-134.
  10. Orsavova, J et al. (2015). Fatty Acids Composition of Vegetable Oils and Its Contribution to Dietary Energy Intake and Dependence of Cardiovascular Mortality on Dietary Intake of Fatty Acids. International Journal of Molecular Sciences 16(6): 12871-12890.
  11. Krut, LH, Bronte-Stewart, B (1964). The fatty acids of human depot fat. Journal of Lipid Research 5(3): 343-351.
  12. Turner, SE et al. (2017). Molecular Pharmacology of Phytocannabinoids. In Kinghorn, AD; Falk, H; Gibbons, S; Kobayashi, J (eds.). Phytocannabinoids: Unraveling the Complex Chemistry and Pharmacology of Cannabis sativa. Progress in the Chemistry of Organic Natural Products 103. Springer International Publishing: 61–101.
  13. De Petrocellis, L et al. (2011). Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. British Journal of Pharmacology 163(7): 1479-1494.
  14. Capano, A et al. (2020). Evaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients: a prospective cohort study. Postgraduate Medicine 132(1): 56-61.
  15. Casarett, DJ et al. (2019). Benefit of Tetrahydrocannabinol versus Cannabidiol for Common Palliative Care Symptoms. Journal of Palliative Medicine 22(10): 1180-1184.
  16. Wagner, H, Ulrich-Merzenich, G (2009). Synergy research: Approaching a new generation of phytopharmaceuticals. Phytomedicine 16(2-3): 97-110.
  17. Rasoanaivo, P et al. (2011). Whole plant extracts versus single compounds for the treatment of malaria: synergy and positive interactions. Malaria Journal 10(Suppl.1): 1-12.
  18. Yuan, H et al. (2017). How Can Synergism of Traditional Medicines Benefit from Network Pharmacology? Molecules 22(7): 1135-1153.
  19. McPartland, JM, Russo, EB (2001). Cannabis and Cannabis Extracts: Greater Than the Sum of Their Parts? Journal of Cannabis Therapeutics 1(3-4): 103-132.
  20. Russo, E (2011). Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology 163(7): 1344-1364.
  21. Pamplona, FA et al. (2018). Potential Clinical Benefits of CBD-Rich Cannabis Extracts Over Purified CBD in Treatment-Resistant Epilepsy: Observational Data Meta-analysis. Frontiers in Neurology 9: 759.
  22. Zafar, R et al. (2021). Medical cannabis for severe treatment resistant epilepsy in children: a case-series of 10 patients. BMJ Paediatrics Open 5: e001234.
  23. Gallily, R et al. (2015). Overcoming the Bell-Shaped Dose-Response of Cannabidiol by Using Cannabis Extract Enriched in Cannabidiol. Pharmacology and Pharmacy 6: 75-78.
  24. Lewis, MA et al. (2018). Pharmacological Foundations of Cannabis Chemovars. Planta Medica 84(04): 225-233.
  25. Karniol, IG et al. (1974). Cannabidiol interferes with the effects of delta 9- tetrahydrocannabinol in man. European Journal of Pharmacology 28(1): 172– 177.
  26. Zuardi, AW et al. (1982). Action of cannabidiol on the anxiety and other effects produced by δ9-THC in normal subjects. Psychopharmacology (Berl) 76(3): 245–250.
  27. Bhattacharyya, S et al. (2010). Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 35(3): 764-774.

These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.